BCL2 and myelodysplastic syndrome: Overall, our data show that miR-192-5p targets BCL2 and its expression might correlate with response to AZA + LEN therapy, possibly leading to several new lines of investigation relevant for both an improvement of patients’ stratification during AZA + LEN therapy and a better comprehension of miRNA regulation in MDS.